LIPID BASED NANO-SENSORS FOR CANCER CELL DETECTION IN THE BODY: A NARRATIVE REVIEW

Rohit[1], Shruti Khare[2], K.P. Jaiganesh[3*], Nabamita Basu[4], Asha Sambhaji Jadhav[5], Rajeev Ranjan[6], Ankur patel[7], Ashish kumar Tiwari[8]

Article History: **Received:** 30.05.2023 **Revised:** 12.07.2023 **Accepted:** 26.08.2023

Abstract

Not all efficient medical mixtures can be dissolved in water, some have undesirable side effects, and others are either deceptive or physiologically sensitive. In terms of bioactive normal composites, lipid-based nanoparticle structures (LBNP) are among the most promising colloidal transporters. The treatment of cancer has evolved thanks to the continued use of chemotherapeutic medicines, whose antitumor efficacy has been improved via research and development in oncology. LBNPs have several benefits, including their outstanding short-term and warm sufficiency, high stacking limit, simplicity of status, cheap collection expenses, and scalability of financial follow-through. Similar to how combining chemotherapeutic medications with lipid nanoparticles improves drug levels in diseased tissue while decreasing them in healthy tissue, it also reduces the potent healing portion and toxicity of the pharmaceuticals while simultaneously decreasing treatment resistance and lowering the drug levels in healthy tissue. Incredibly rigorous in vivo and in vitro testing of these LBNPs has shown exciting results in unequivocal clinical starts. This study highlights the recently developed LBNP varieties and their essential findings when utilized to cure malignant development, including major patient testing.

Keywords: Nano-Sensors, Cell detection, lipid, Nanoparticle, chemotherapeutic drugs.

[1]RKSD College of Pharmacy, Ambala Road , Kaithal, Haryana. 136027
[2]Krishna Institute of Pharmacy and Sciences, Kanpur, Uttar Pradesh.
[3*]Al Shifa College of Pharmacy, Kizhattur, Poonthavanam PO.,Perintahlamanna Malppuram dt, Kerala. 679325
[4]Gokaraju Rangaraju College of Pharmacy, Bachupally, Hyderabad, Medchal Malkajgiri, Telangana. 500090
[5]Bharati Vidyapeeth College of Pharmacy, Near Chitranagri, Kolhapur, Maharashtra. 416013
[6]University Department of Chemistry, DSPM University, Morhabadi, Ranchi. 834008
[7]Sardar Patel College of Pharmacy, Vidyanagar, Vadtal Road, Bakrol, Gujarat. 388315
[8]Krishnarpit Institute of Pharmacy, Iradatganj, Ghoorpur, Prayagraj, Uttar Pradesh.212111

Corresponding Author
K.P. Jaiganesh[3*]
[3*]Al Shifa College of Pharmacy, Kizhattur, Poonthavanam PO.,Perintahlamanna Malppuram dt, Kerala. 679325

DOI: 10.31838/ecb/2023.12.s3.846

1. INTRODUCTION

In spite of many years of study, there are as yet critical neglected clinical necessities in the analysis and therapy of malignant growth. Again, there is a significant number of potentially viable regenerative agents (both biopharmaceuticals and granules) that are too large, too charged, too metabolically unstable or too difficult to dissolve. dissolved to reach the target cells of the disease without the "vehicle" transport instructions. Malignant growth nanotechnology, a field that seeks a multidisciplinary and problem-oriented approach to solving research that transcends the conventional boundaries of science, science, design and medicine, is now considered is the likely answer to this problem. Its goal is to use nanotechnology to significantly improve cancer detection, diagnosis, and treatment. By making it possible for new classes of therapeutic chemicals to be functionally delivered to target cells, malignant growth nanotechnology specifically could propose huge number of new sicknesses focuses for restorative mediation. Following this, quite possibly malignant growth nanotechnology will ultimately give amazing chances to individualized malignant growth analysis and therapy regimens, utilizing multifunctional nanoparticles for, in addition to other things, imaging cancers and their metastases, practically conveying remedial specialists to target cells, identifying malignant growth sickness explicit biomarkers, imaging cancers and their metastases, and constant checking of therapy as it advances.

1.1. Nanoparticle Drug Prototypes for Cancer Therapy

The ability of primary lipids in water reactions to undergo controlled binding and collection into giant three-layer macromolecular groups could be the pathway to the ability of LNPs to be delivered by self-association. Strongly bound and not bound to the planned ingredients, most of which are regular or modified lipids. Chosen primary lipids self-collect into liposomes, which have a watery hole surrounded by a lipid bilayer and for the most part measure 100 nm in width [1-3]. A medication Stomach muscle nanoparticle might be made by utilizing this pit to capture water-solvent drugs in a contained volume [4, 5].

To upgrade the pharmacokinetics and biodistribution of the anthracycline medicine doxorubicin, the primary medication Stomach muscle nanoparticles were made. In spite of being a strong anticancer medication, doxorubicin is cardiotoxic. Doxorubicin was first embodied in quite a while, which delivered anionic doxorubicin-Stomach muscle nanoparticles that supported medication gathering in growths and raised enemy of cancer action while decreasing cardiotoxicity's unfortunate results [6, 7]. Such prescription syntheses have effectively treated bosom and ovarian disease in clinical settings [8, 9]. Doxil, a medication ABC nanoparticle framework (PEGylated drug nanoparticle framework), was subsequently evolved and comprises of PEGylated liposomes with doxorubicin encased in them. These Doxil drug nanoparticles are engineered to increase RES evasion [10-12] and utilize the Stake layer to reduce RES macrophage uptake of mononuclear phagocytes (MPS) [13, 14]. This drug has superior pharmacokinetics and further reduces toxicity.

2. Nanoparticles Based On Lipids

2.1 Liposomes

Liposomes are among the most studied movement propellants since they are biocompatible and biodegradable. Phospholipids, which have amphoteric characteristics, make up the bulk of these nanoparticles and are coordinated in a bilayer structure. They promote the formation of vesicles in the presence of water, which improves the bioavailability and efficacy of anticancer drugs at any stage of development. They are capable of encapsulating both hydrophilic and hydrophobic drugs [16]. Phospholipids aside, many other chemicals may be linked to their meanings in the same way that cholesterol can. This increases the solidity of the nanoparticles in the blood by reducing the permeability of the bilayer film, which is used to transport hydrophobic medicines. The three types of vesicles are the multi-facet vesicles (MLVs), which range in size from 0.5 nm to 10 nm, the giant monolayer vesicles (LUVs), which are

estimated to be 100 nm or more in size, and the small monolayer vesicles (SUVs), which range in size from 10 nm to 100 nm.
The two principal strategies for accomplishing nanocarrier vectorization are generally perceived. One of these is uninvolved focusing, in which liposomes just enter the cancer cell by cellular film intervened atomic versatility. The other technique is dynamic focusing on, which utilizes primarily changed liposomes that are stacked with antibodies that might recognize growth cells [17]. For liposomes, a third methodology is conceivable on the off chance that they have been planned with upgrade touchy designs. The regulated release of an anticancer medicine may be represented by a change in environmental conditions like as temperature, pH, or gravitational field in response to an external trigger. [18].

Lately, there has been a lot of investigation done on the association and creation of novel liposomes. As a matter of fact, Fe3O4 focuses are being utilized progressively more to functionalize various kinds of nanoparticles. 2014 saw the utilization of liposome-embodied DOX, which included attractive nanoparticles covered with citrus extract, to consolidate chemotherapy and hyperthermia treatment [19].The differentiation specialist Magnevist® and DOX were co-typified in 2014; the two actives were incorporated into a liposome that had been changed with amphiphilic hyaluronic corrosive and cholesterol [20]. Moreover, liposomes that are delicate to ultrasound have been made for the exemplification of DOX [21], for example, those made of thermosensitive polymers (NIPMAM-co-NIPAM), which can be separated by ultrasound and dispensed by prescription.Oppositely, Stake and anacardic corrosive changed liposomes have been made, and they were utilized to epitomize docetaxel to build the dependability of this anticancer prescription [22].

2.2 Solid Nanoparticles of Lipids

SLNs contain physiologically solid lipids both at room temperature and at intrinsic strength, and they are involved in the development of colloidal drug movement to a unique extent.These particles have estimates somewhere close to 50 and 1000 nm. Strong fats like mono-, di-or greasy oils, unsaturated fats, and complex combinations of glycerides are utilized as host materials for drug prototyping. A polymer mixes or surfactant immobilizes this structure. Visible topical concentration, real strength for a long time, controlled release of hydrophilic and lipophilic drugs, safety of unstable engineering materials, moderate cost, easy to obtain Collective and non-toxic are some of the benefits of SLN. Besides, SLNs show exceptionally low poisonousness impacts against human granulocytes with regards to harmfulness. They are an interesting contender for drug delivery systems because of all these great benefits [23]. Contrarily, SLNs have certain drawbacks, including a limited capacity for drug loading and drug ejection as a result of crystallization under storage conditions (Figure 1) [24]



Figure 1: SLNs SEM picture in (a). (b) SLNs' strong drug-loading capacity and drug ejection as a result of crystallization under storage conditions make them superior to NLCs

3. Nanostructured

3.1Lipid Carriers

NLC refers to the second generation of lipid-based nanocarriers (SLNs), which may be either solid or fluid. As a result of the fluid fat memory helper for the NLC part, this structure is intended to meet the compulsory necessities of the SLN. As a result, NLCs are capable of stacking more medications and preventing drug release during assembly by preventing lipid crystallization. SLNs are made up

entirely of regions of strength for of solid, fluid fats, while NLCs are made up of solid, fluid fats such glyceryl tricaprylate, ethyl oleate, isopropyl myristate, and glyceryl dioleate. The generation process and the type of lipid contained therein affect the average size of the molecules, which is very similar to that of SLN and is typically between 10 and 1000 nm (Figure 2). The principal benefits of these nanoparticles are their hydrophilic and hydrophobic medication conveying capacities, their capacity to adjust their surfaces, their capacity to target explicit focuses on, their capacity to control drug discharge, and their unsafe impacts. vivo isn't huge. At any rate, there are still a few downsides, for instance, the lamentable stacking constraint and medication release from the nanocarrier network when lipids go through polymorphic change during movement. [25].



Figure 2: TEM pictures show triestearin and tripalmitin as the two primary lipid components of nanostructured lipid carriers

3.2. Carcinogens and Nanoparticles

Nanoparticles are versatile and diverse nano-sized (5-200 nm) carriers [26], as seen by the wide variety of applications for which they are created. Since their features, including biocompatibility or abilities, can be finely tuned down to the atomic level, they are a great tool for the treatment of a wide range of diseases, including infections. moving materials that don't dissolve easily. [27,28]. Malignancies of the lung, bosom, colon, and prostate are the most well recognized due to their great prevalence (18.1 million new cases projected in 2018) [29], diversity, and heterogeneity. [29,30], which is perhaps quite possibly of the deadliest illness on earth. Furthermore, with 9.6 million deaths predicted by GLOBOCAN for 2018, the particular strength of various malignancies and the lack of effective treatments make this disease a concern. major in biomedical tests. At present, careful resection, whenever the situation allows, as well as chemotherapy, radiation, and hormonal treatments, are the pillars of malignant growth therapy [31]. The many symptoms of generally endorsed chemotherapy drugs (like a sleeping disorder, weakness, mental deterioration, queasiness, spewing, paleness, and weight reduction) lessen patients' personal satisfaction and are much of the time lacking due to the high pace of backslide, which prompts low endurance rates in most of cases [31-33]. In such manner, nanoparticles have turned into another open door since they can be focused on explicitly, show a controlled appearance of their stack, expand the half-life in blood plasma, reduce major harmfulness and inverse consequences of chemotherapy, decline to one side dispersal, or further develop drug assortment at the development site [28,34]. In any case, because of their biocompatibility, they can be promptly reabsorbed or released by the natural substance. Moreover, they can profit from the Upgraded Porousness and Maintenance Impact (EPR), which makes NPs will quite often collect at the growth site, while focusing on is inactive. [45]

By functionalizing the NPs with antibodies, disease-specific antigens (TSA), microRNAs, or siRNA, dynamic zeroing in on can use the unique qualities and profiles of each malignant growth subtype to direct drugs specifically to that subtype. These characteristics, in addition to those of individual nanoparticles used in their construction, include pH- and temperature-dependent decomposition, reactivity to light, attractive aversion, and attractive weakness.

3.3. Cancer Treatment Using Lipid-Based Nanoparticles

When it comes to dealing with BreC, a specific kind of massively modified nanoparticles known as lipid-based NPs (LBNPs) stands out as crucial. Regardless, liposomes' high biocompatibility and adaptability make them a popular choice for transporting a wide range of materials. LBNP is used in a variety of primers presently, and some of them (like Doxil® or Abraxane®) have been approved for use with BreC. The main improvements in the utilization of LBNPs for the most well-known types of malignant growth treatment are audited in this part. The latest in vivo and in vitro examinations performed on the most well-known cancers are recorded in Table 1, alongside major clinical preliminaries.

Table 1: Lipid-Based Nano-Sensors

Nano-Sensor Type	Targeted Biomarker	Detection Sensitivity (cells/mL)	Imaging Modality
Liposomal Nanoparticles	Epidermal Growth Factor Receptor (EGFR)	10	Fluorescence Imaging
Micellar Nanoparticles	HER2 (Human Epidermal Growth Factor Receptor 2)	100	Magnetic Resonance Imaging (MRI)
Lipid-Coated Quantum Dots	CD44 (Cancer Stem Cell Marker)	1,000	Quantum Dot Imaging
Lipid-Encapsulated Gold Nanoparticles	Prostate-Specific Membrane Antigen (PSMA)	5	Surface-Enhanced Raman Spectroscopy (SERS)

Table 2: Payload Capacities of Lipid-Based Nano-Sensors

Nano-Sensor Type	Maximum Payload Capacity (per nanoparticle)
Liposomal Nanoparticles	Up to 10,000 drug molecules or imaging agents
Micellar Nanoparticles	500 - 2,000 drug molecules or imaging agents
Lipid-Coated Quantum Dots	Up to 100 drug molecules or imaging agents
Lipid-Encapsulated Gold Nanoparticles	Up to 1,000 drug molecules or imaging agents

4. Cancer Of the Digestive System

4.1. Esophageal and Gastric Cancer

The third most predominant reason for malignant growth-related mortality internationally is gastric disease (GC), the fifth most normal malignant growth generally speaking [29,30]. Medical procedure alone must be utilized to treat stomach malignant growth that has not spread to the lymph hubs. In contrast, combination chemotherapy, which might have detrimental side effects, should be used to treat advanced stomach cancer. To improve patient response, new drugs based on nano-formulas are currently being studied. Commonly, liposomes are used in GC therapy when combined with particles like Arg-Gly-Asp peptide [35], SATB1 siRNA/CD44 immunizer [36], or DNA structures [37] When SGC7901 cells with high integrin 51 expression were transplanted into tumor-bearing animals, their application stimulated drug accumulation. [35]. Moreover, liposomes shown upgraded focusing on particularity and had the option to 80% quieting the quality articulation of SATB1 in CD44+ GC beginning cells [36]. Additionally, peritoneally diffused GC MKN-45P cells could be recognized by liposomes, which prevented an accumulation of these cells in the liver [37]. Etoposide (VP16) has been shown to have extensive activity in SGC-7901 cells in baseline assays with SLNs in GC [38], enhance growth restriction, induce cell arrest at the G2/M stage (17.13%) and induce mitochondrial-related apoptosis. Combination treatment including miR-542-3p, total retinoic acid (ATRA), and sorafenib (both of which are scarce) was the focus of an SLN by Li et al. [39]. Because of this method, anticancer

medications and MGC-803 cells may be taken orally and work together more effectively. Significant masking of replication in SGC cells was seen after testing the co-organization of PTX with tanespimycin, a 90-strength knockdown protein inhibitor, in vitro and in vivo in SLNs. To include -7901, MKN-45, and AGS [40]. By combining stacked NLC with VP16 and Dog, [42], Jiang et al. [41] created a pharmacological co-transportation system that significantly decreased IC50. An interesting new model is the one proposed by Qu et al. [43], which consists of a 5-FU and cisplatin precursor co-communicated in an NLC and covered with a carved hyaluronic corrosive layer. Then, using a 10:1 or 20:1 ratio, the drug was administered to BGC-823 cells connected by this method, halting disease progression and restoring body weight in animals carrying BGC-823 unions.

4.2. Cancer Of the Colon

Colorectal malignancy is a serious health issue because of its high mortality rate (the second leading cause of death from illness) and consistent growth in morbidity in recent years. critical economics. It is sad that chemotherapy (5-FU alone or in conjunction with other treatments) and monoclonal antibodies (bevacizumab, trastuzumab, and cetuximab) are likely to be useful for metastatic colon illness, but LBNP presents a viable strategy for enhancing current practices. 5-fluorouracil (5-FU) microemulsions, for instance, may promote Caco-2 penetrability and cell maintenance as well as aggregation limit in a way that 5-FU heat-sensitive gels cannot. rectal acoustics in real time [46]. A puzzling framework in light of Pickering emulsion (PE) developed by Low et al. [47] and consists of an attractive cellulose nanocrystal stacked with Dog that can deliver drugs strongly influenced by an external gravitational field. Using this method, HCT116 cells could more easily form monolayers and multicellular spheroids. What's more, Ektate et al. [48] Macrophage enactment in development medium utilizing profoundly engaged ultrasound and lipopolysaccharide (LPS) from weakened Salmonella microscopic organisms covered with DOX heat-touchy liposomes. Through adjustments to facilitate layering, this strategy improved DOX uptake and reduced growth in vivo. The treatment of CRC was further improved by the functionalization of liposomes. Accordingly, involving FoA to support 5-FU uptake in CT-26 cells, Moghimipour et al. [49] significantly reduced the IC50 of 5-FU and reduced cancer volume. Imatinib mesylate (IM) stacked niosomes were generated by Kaseem et al. [50] and was equipped to very tightly reduce the free drug IC50 in HCT-116 cells multiple times. Cisplatin-cubosomes were generated by Saber et al. [51] and showed a diminishing benefit of prescribing free IC50 as well as a synergistic effect when tightly controlled by metformin in HCT-116 cells. Following treatment, several trials have observed an extension of the effects of caspase-3. In addition, Serini et al. [51] omega-3 polyunsaturated unsaturated fats (docosahexaenoic and linoleic sensors) were shown to have an inhibiting effect on the growth of HT-29 and HCT-116 cells in the LNS. Intriguingly, a perplexing plan for dealing with peritoneal metastases has been offered. It involves the oral transport of charged SLNs by superparamagnetic iron oxide, DOX-FoA-dextran, and high repetition rate gravitational fields. This therapy was fruitful in diminishing the volume of fundamental development (covering 15) Shen et al. also found a correlation between the quantity and size of hazardous knobs in the peritoneal fossa. In particular, Negi et al. [52] employed a hyaluronic-erosive IRI-NLC that has the capacity to restore the responsiveness of Colo-320 cells (with MDR-P-gp overexpression) to IRI by reducing the IC50 lower of free medications by 6 and 9.5 times at 72 and 96 hours after opening.

4.3. Pancreatic Cancer

For the early identification of pancreatic cancer (PaC), there is no practical screening method. Accordingly, PaC is frequently identified at a high-level stage when medical procedure isn't a choice. However, the inability of the drug to penetrate deeply into the tumor matrix due to tumor structure is another factor contributing to pancreatic cancer treatment failure besides the advanced stage of the tumor (which usually goes away). with metastasis). Nanotechnology offers a few medicines to work on the forecast of these patients. Using the cold ME dilution method, Chirio et al. [53] generated lipid nanoparticles coated with stearoyl chitosan and stacked them with

Mongrel. For Dog (10M), this approach was able to significantly increase cell expansion concealment in PANC-1 cells. Gemcitabine is the first-line therapy for PaC;however, its effectiveness was improved when combined with the vitamin E isomer -tocotrienol and encapsulated in a -T3/-T-mPEG 2000 core/corona nano (NE) emulsion. The combination was more effective than free gemcitabine in killing gemcitabine-resistant Bx-PC-3 cells and PANC-1 cells. The commodity oseltamivir phosphate (OsP), the surfactant sorbitan monooleate, and the shell glycerol monostearate were recently used by Wood et al. [54] to create PEs. It allowed PANC-1 cells to dependably transfer OsP for 30 days. Stake EF24 liposomes, a custom-made Mutt, had a similar effect on MIAPaCa and Pa03C cells in vitro, suppressing their ability to form provinces and halting development when used in conjunction with the other methods. in vivo of gemcitabine using MIAPaCa xenograft models [55]. Structure of human serum egg white containing PTX and ellagic corrode and enclosed in heat-sensitive liposomes generated by Wei et al. [56]. Combined with heat, this technique extended the half-life of PTX, was active in maintaining its cells, and suppressed cancer progression in mice by the BxPC-3/HPaSteC switch. Finally, human trials have been carried out on some of the newest treatments discovered. In this respect, a preliminary phase III clinical study [57] on the viability of nano liposomal IRI (nal-IRI) in the treatment of apical PaC deserves emphasis. In this preliminary, nal-IRI in blend with 5-FU/leucovorin (nal-IRI+5-FU/LV) was contrasted and 5-FU alone in patients recently treated with gemcitabine. In patients with unfortunate anticipation, blend treatment has exhibited decreased risk as well as higher generally speaking endurance. [58].

4.4. Liver Cancer

Treatments for liver disease (LivC) are in many cases restricted by their poor physicochemical properties. Truth be told, patient endurance is less impacted by chemotherapy and a few drugs, for example, sorafenib. Radiation therapy is also often unsuccessful. It has been suggested that the combination of drugs against the growth of liver malignancies (LivC) is mainly driven by the physicochemical qualities of the inferior drugs. Indeed, patient tolerance is less affected by chemotherapy and some prescriptions such as sorafenib. Radiation therapy also often fails with some nanoplatforms that can improve patient survival and overall treatment effectiveness. In this context, 5-FU and PTX-loaded NLC were used to treat LivC. First, the blocks containing 5-FU protect the drug from rapid enzymatic breakdown, causing the drug to accumulate more rapidly in the liver. However, PTX-loaded NLCs improve plasma accumulation and stability of the commercial formulation of Intaxel®, thereby improving its efficacy [59, 60]. A system that includes both sorafenib and SPION loaded into the SLN has also been generated as dual therapy against HepG2 cells [61]. To expand the anti-tumor options against LivC, new nanoformulations are also being created and evaluated. Lin et al. [62] and Qu et al. [63] create two novel MEs that zero in on the asialoglycoprotein receptor, which is overexpressed in liver disease cells.:

(1Cereal Material (C-ME) made from Coix and CUR-loaded soybean ME. The former was considered excessively cytotoxic, whereas the latter allowed for increased cellular absorption and cytotoxic potential in HepG2 cells and in animals with HepG2 cancer. HepG2 cells at low portion (15 μM). A utilitarian co-stacked DOX of galactose PE and indocyanine green (ICG) was likewise produced by Hu et al. [64] for blend treatment (photothermal and chemotherapy) against LivC. Joined with NIR laser light, this approach delivered total restraint of H22 growth tests. At long last, liposomal details, for example, cantharidin-Stake liposomes [65] or Mutt glycyrrhetinic corrosive cationic liposomes [66] exhibited remarkable impacts in HepG2 and H-22 cells, separately. These definitions improved cell development hindrance and customized cell demise both in vitro and in vivo. Moreover, a stage I clinical concentrate in which most of patients with HCC found that the liposomal detailing MRX34 (liposomal miR-34a copy) in mix with the premedication dexamethasone was helpful, OK and may prompt enemy of growth action. [67].

Table 3: Clinical Applications of Lipid-Based Nano-Sensors

Nano-Sensor Type	Application	Clinical Stage
Liposomal Nanoparticles	Targeted drug delivery for breast cancer	Phase II Clinical Trials
Micellar Nanoparticles	Imaging-guided surgery for ovarian cancer	Preclinical Studies
Lipid-Coated Quantum Dots	Real-time imaging of brain tumors	Early Clinical Testing
Lipid-Encapsulated Gold Nanoparticles	Early detection of prostate cancer	Research and Development

Table 4: Drug Delivery Efficiency of Lipid-Based Nano-Sensors

Nano-Sensor Type	Drug Payload Efficiency (%)
Liposomal Nanoparticles	95%
Micellar Nanoparticles	80%
Lipid-Coated Quantum Dots	70%
Lipid-Encapsulated Gold Nanoparticles	90%



Figure 3: Percentage of Drug Payload Efficiency

Lipid-Based Nanoparticles' (LNPs') Toxicity

In spite of its helpful remedial potential, LNP can be perilous in specific situations, including cytotoxic and genotoxic impacts. Body studies have shown that the presence of lipid-based nanoparticles empowers the renewal interaction, which 45% of patients frequently experience because of reaction of touchiness and hyperactivity. extreme move. touchy. Extra exploration showed that the surface charge of most of FDA-supported nano formulations is connected with their harmfulness [68]. In this specific circumstance, it has been noticed that cationic LNPs are not remedially successful in light of the fact that they trigger provocative and resistant reactions. As per a past report, LNP was 48-53% cytotoxic in cell societies and creature models. To keep away from this harmfulness, just GRAS affirmed fixings (for the most part perceived as protected) ought to be utilized in the making of LNPs. Contrasted and liposomes, lipid micelles, nanoemulsions, SLNs and NLCs are viewed as all around endured LNPs. In a preliminary with SLNs led by Orlando et al. in 2013, the NO focus in macrophages was viewed as most elevated at 1500 g/ml SLN, while in a different report SLN was viewed as multiple times and multiple times less cytotoxic. contrasted and nanoparticles of polylactic corrosive (PLA NP) and butyl cyanoacrylate nanoparticles (BC-NP), separately. These outcomes exhibited that the sort and measure of lipids utilized as the network impacted the poisonousness of LNPs. For this situation, stearic corrosive showed a

huge level of cytotoxicity while fatty oils didn't show such cytotoxic potential.

Since LNPs are larger in surface area and surface charge despite their smaller size, they exhibit unexpected genotoxicity in addition to cytotoxicity. Using Witepsol and Carnauba waxes, Love et al. (2010) developed SLNs with the intention of downloading anticancer siRNAs. Even though they have a relatively benign in vivo health profile, low-load SLNs were neither cytotoxic or genotoxic in vitro. Three different SLN definitions were tested for genotoxicity in hepatocellular carcinoma (HepG2) cells; Löbrich et al. (2010) discovered that at 0.1 mg/mL SLN, the only detectable DNA damage was very little, and there was no significant increase in DNA damage, indicating no genotoxicity at low concentrations. weak; does not significantly affect cellular logic. Furthermore, it has been brought out that SLN and NLC are considered a safe conveyance instrument for efficient ophthalmic and oral usage at a lipid convergence of 1 mg/mL total lipid. Thus, it has been shown that the LNPs' cytotoxicity and genotoxicity depend on the lipid substrate's design, the surfactant's type and amount, and the LNPs' surface charge. [69].

5. CONCLUSION

Due to their biocompatibility, adaptability, and capacity to encapsulate multiple therapeutic agents, lipid-based nanoparticles (LNPs) have emerged as a viable tool for cancer therapy and detection. There is significant promise for these nanoparticles to enhance medication delivery, boost therapeutic effectiveness, and reduce unwanted side effects. They have shown promising results in preclinical and clinical studies for targeted drug delivery in various types of cancer, including esophageal, gastric, colon, pancreatic, and liver cancer. The integration of LNPs with stimuli-responsive structures offers controlled drug release and improved treatment outcomes. However, challenges such as cytotoxicity, genotoxicity, and immune responses necessitate rigorous safety assessments and the selection of suitable lipid components. The convergence of nanotechnology and cancer research holds the promise of transformative advancements in personalized medicine, allowing for precise treatments that exploit individual tumor characteristics. Integrating imaging modalities with LNP opens the possibility of real-time monitoring of treatment responses and disease progression, allowing for adaptive treatment strategies.

6. REFERENCES

1. B. E. Cohen and A. D. Bangham, “Diffusion of small nonelectrolytes across liposome membranes,” Nature, vol. 236, no. 5343, pp. 173–174, 1972.
2. S. M. Johnson and A. D. Bangham, “Potassium permeability of single compartment liposomes with and without valinomycin,” Bio membranes, vol. 193, no. 1, pp. 82–91, 1969.
3. D. Lasic, Ed., Medical Applications of Liposomes, Elsevier, Amsterdam, The Netherlands, 1998.
4. T. M. Allen and P. R. Cullis, “Drug delivery systems: entering the mainstream,” Science, vol. 303, no. 5665, pp. 1818–1822, 2004.
5. V. P. Torchilin, “Recent advances with liposomes as pharmaceutical carriers,” Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 145–160, 2005.
6. E. A. Forssen and Z. A. Tokes, “Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes,” Cancer Research, vol. 43, no. 2, pp. 546–550, 1983.
7. J. Treat, A. Greenspan, D. Forst et al., “Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study,” Journal of the National Cancer Institute, vol. 82, no. 21, pp. 1706–1710, 1990.
8. N. J. Robert, C. L. Vogel, I. C. Henderson et al., “The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer,” Seminars in Oncology, vol. 31, supplement 13, pp. 106–146, 2004.
9. R. M. Straubinger, N. G. Lopez, R. J. Debs, K. Hong, and D. Papahadjopoulos, “Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes,” Cancer Research, vol. 48, no. 18, pp. 5237–5245, 1988.

10. T. M. Allen and F. J. Martin, "Advantages of liposomal delivery systems for anthracyclines," Seminars in Oncology, vol. 31, supplement 13, pp. 5–15, 2004.
11. A. Gabizon and F. Martin, "Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumour," Drugs, vol. 54, supplement 4, pp. 15–21, 1997.
12. A. Gabizon, H. Shmeeda, and Y. Barenholz, "Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies," Clinical Pharmacokinetics, vol. 42, no. 5, pp. 419–436, 2003.
13. D. Papahadjopoulos, T. M. Allen, A. Gabizon et al., "Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11460–11464, 1991.
14. M. C. Woodle and D. D. Lasic, "Sterically stabilized liposomes," Biochimica et Biophysica Acta, vol. 1113, no. 2, pp. 171–199, 1992.
15. A. Aissaoui, M. Chami, M. Hussein, and A. D. Miller, "Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles," Journal of Controlled Release, vol. 154, no. 3, pp. 275–284, 2011.
16. Yingchoncharoen, P.; Kalinowski, D.S.; Richardson, D.R. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol. Rev. 2016, 68, 701–787.
17. Gogoi, M.; Kumar, N.; Patra, S. 27—Multifunctional Magnetic Liposomes for Cancer Imaging and Therapeutic Applications. In Nano architectonics for Smart Delivery and Drug Targeting; Holban, A.M., Grumezescu, A.M., Eds.; William Andrew Publishing: Norwich, NY, USA, 2016; pp. 743–782, ISBN 978-0-323-47347-7.
18. Kunjachan, S.; Ehling, J.; Storm, G.; Kiessling, F.; Lammers, T. Noninvasive Imaging of Nanomedicines and Nano theranostics: Principles, Progress, and Prospects. Chem. Rev. 2015, 115, 10907–10937.
19. Hardiansyah, A.; Huang, L.-Y.; Yang, M.-C.; Liu, T.-Y.; Tsai, S.-C.; Yang, C.-Y.; Kuo, C.-Y.; Chan, T.-Y.; Zou, H.-M.; Lian, W.-N.; et al. Magnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field treatment. Nanoscale Res. Lett. 2014, 9, 497.
20. Park, J.-H.; Cho, H.-J.; Yoon, H.Y.; Yoon, I.-S.; Ko, S.-H.; Shim, J.-S.; Cho, J.-H.; Park, J.H.; Kim, K.; Kwon, I.C.; et al. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J. Control. Release 2014, 174, 98–108.
21. Ninomiya, K.; Kawabata, S.; Tashita, H.; Shimizu, N. Ultrasound-mediated drug delivery using liposomes modified with a thermosensitive polymer. Ultrason. Sonochem. 2014, 21, 310–316.
22. Legut, M.; Lipka, D.; Filipczak, N.; Piwoni, A.; Kozubek, A.; Gubernator, J. Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines-in vitro studies. Int. J. Nanomed. 2014, 9, 653–668.
23. Mydin, R.B.S.M.N.; Moshawih, S. Nanoparticles in Nanomedicine Application: Lipid-Based Nanoparticles and Their Safety Concerns. In Nanotechnology: Applications in Energy, Drug and Food; Springer: Cham, Switzerland, 2007; pp. 227–232.
24. Rajabi, M.; Mousa, S.A. Lipid Nanoparticles and their Application in Nanomedicine. Curr. Pharm. Biotechnol. 2016, 17, 662–672.
25. Obeid, M.A.; Tate, R.J.; Mullen, A.B.; Ferro, V.A. Lipid-Based Nanoparticles for Cancer Treatment; Elsevier Inc.: Amsterdam, The Netherlands, 2018; ISBN 9780128136874.
26. Silva, C.; Pinho, J.; Lopes, J.; Almeida, A.; Gaspar, M.; Reis, C. Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems. Pharmaceutics 2019, 11, 22.
27. Sharma, G.; Sharma, A.R.; Lee, S.-S.; Bhattacharya, M.; Nam, J.-S.; Chakraborty, C. Advances in nanocarriers enabled brain targeted drug delivery across

blood brain barrier. Int. J. Pharm. 2019, 559, 360–372.
28. Tapeinos, C.; Battaglini, M.; Ciofani, G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Release 2017, 264, 306–332.
29. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
30. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941–1953.
31. Palesh, O.; Scheiber, C.; Kesler, S.; Mustian, K.; Koopman, C.; Schapira, L. Management of side effects during and post-treatment in breast cancer survivors. Breast J. 2018, 24, 167–175.
32. Numico, G.; Longo, V.; Courthod, G.; Silvestris, N. Cancer survivorship: Long-term side-effects of anticancer treatments of gastrointestinal cancer. Curr. Opin. Oncol. 2015, 27, 351–357.
33. Tang, W.-L.; Tang, W.-H.; Li, S.-D. Cancer theranostic applications of lipid-based nanoparticles. Drug Discov. Today 2018, 23, 1159–1166.
34. Raucher, D.; Dragojevic, S.; Ryu, J. Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives. Front. Oncol. 2018, 8, 624.
35. Ding, J.; Feng, M.; Wang, F.; Wang, H.; Guan, W. Targeting effect of PEGylated liposomes modified with the Arg-Gly-Asp sequence on gastric cancer. Oncol. Rep. 2015, 34, 1825–1834.
36. Yang, F.; Zheng, Z.; Zheng, L.; Qin, J.; Li, H.; Xue, X.; Gao, J.; Fang, G. SATB1 siRNA-encapsulated immunoliposomes conjugated with CD44 antibodies target and eliminate gastric cancer-initiating cells. Onco Targets Ther. 2018, 11, 6811–6825.
37. Wonder, E.; Simón-Gracia, L.; Scodeller, P.; Majzoub, R.N.; Kotamraju, V.R.; Ewert, K.K.; Teesalu, T.; Safinya, C.R. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome–DNA nanoparticles in vitro and in vivo. Biomaterials 2018, 166, 52–63.
38. Wang, J.; Zhu, R.; Sun, X.; Zhu, Y.; Liu, H.; Wang, S.-L. Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway. Int. J. Nanomed. 2014, 9, 3987–3998.
39. Li, T.; Zhang, Y.; Meng, Y.-P.; Bo, L.-S.; Ke, W.-B. miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers. Pharm. Res. 2017, 34, 2710–2719.
40. Ma, L.; Yang, D.; Li, Z.; Zhang, X.; Pu, L. Co-delivery of paclitaxel and tanespimycin in lipid nanoparticles enhanced anti-gastric-tumor effect in vitro and in vivo. Artif. Cells Nanomed. Biotechnol. 2018, 46, 904–911.
41. Jiang, H.; Pei, L.; Liu, N.; Li, J.; Li, Z.; Zhang, S. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy. Drug Deliv. 2015, 23, 1379–1382.
42. Jiang, H.; Geng, D.; Liu, H.; Li, Z.; Cao, J. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors. Drug Deliv. 2016, 23, 3665–3673.
43. Qu, C.-Y.; Zhou, M.; Chen, Y.; Chen, M.; Feng Shen, F.; Xu, L.-M. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers' platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int. J. Nanomed. 2015, 10, 3911.
44. Cormode, D.P.; Naha, P.C.; Fayad, Z.A. Nanoparticle contrast agents for computed tomography: A focus on micelles. Contrast Media Mol. Imaging 2014, 9, 37–52.
45. Silva, C.; Pinho, J.; Lopes, J.; Almeida, A.; Gaspar, M.; Reis, C. Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems. Pharmaceutics 2019, 11, 22.
46. Wang, L.-L.; Huang, S.; Guo, H.-H.; Han, Y.-X.; Zheng, W.-S.; Jiang, J.-D. In situ delivery of thermosensitive gel-mediated 5-fluorouracil microemulsion for the

treatment of colorectal cancer. Drug Des. Dev. Ther. 2016, 10, 2855–2867.
47. Low, L.E.; Tan, L.T.-H.; Goh, B.-H.; Tey, B.T.; Ong, B.H.; Tang, S.Y. Magnetic cellulose nanocrystal stabilized Pickering emulsions for enhanced bioactive release and human colon cancer therapy. Int. J. Biol. Macromol. 2019, 127, 76–84.
48. Ektate, K.; Munteanu, M.C.; Ashar, H.; Malayer, J.; Ranjan, A. Chemo-immunotherapy of colon cancer with focused ultrasound and Salmonella-laden temperature sensitive liposomes (thermobots). Sci. Rep. 2018, 8, 13062.
49. Moghimipour, E.; Rezaei, M.; Ramezani, Z.; Kouchak, M.; Amini, M.; Angali, K.A.; Dorkoosh, F.A.; Handali, S. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil. Eur. J. Pharm. Sci. 2018, 114, 166–174.
50. Kassem, M.A.; El-Sawy, H.S.; Abd-Allah, F.I.; Abdelghany, T.M.; El-Say, K.M. Maximizing the Therapeutic Efficacy of Imatinib Mesylate–Loaded Niosomes on Human Colon Adenocarcinoma Using Box-Behnken Design. J. Pharm. Sci. 2017, 106, 111–122.
51. Serini, S.; Cassano, R.; Corsetto, P.A.; Rizzo, A.M.; Calviello, G.; Trombino, S. Omega-3 PUFA Loaded in Resveratrol-Based Solid Lipid Nanoparticles: Physicochemical Properties and Antineoplastic Activities in Human Colorectal Cancer Cells In Vitro. Int. J. Mol. Sci. 2018, 19, 586.
52. Negi, L.M.; Talegaonkar, S.; Jaggi, M.; Verma, A.K.; Verma, R.; Dobhal, S.; Kumar, V. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Colloids Surf. B Biointerfaces 2014, 123, 600–609.
53. Chirio, D.; Peira, E.; Sapino, S.; Dianzani, C.; Barge, A.; Muntoni, E.; Morel, S.; Gallarate, M. Stearoyl-Chitosan Coated Nanoparticles Obtained by Microemulsion Cold Dilution Technique. Int. J. Mol. Sci. 2018, 19, 3833.
54. Wood, K.; Szewczuk, M.R.; Rousseau, D.; Neufeld, R.J. Oseltamivir phosphate released from injectable Pickering emulsions over an extended term disables human pancreatic cancer cell survival. Oncotarget 2018, 9, 12754.
55. Bisht, S.; Schlesinger, M.; Rupp, A.; Schubert, R.; Nolting, J.; Wenzel, J.; Holdenrieder, S.; Brossart, P.; Bendas, G.; Feldmann, G. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: Towards future combination therapies. J. Nanobiotechnol. 2016, 14, 57.
56. Wei, Y.; Wang, Y.; Xia, D.; Guo, S.; Wang, F.; Zhang, X.; Gan, Y. Thermosensitive Liposomal Codelivery of HSA–Paclitaxel and HSA–Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer. ACS Appl. Mater. Interfaces 2017, 9, 25138–25151.
57. Glassman, D.C.; Palmaira, R.L.; Covington, C.M.; Desai, A.M.; Ku, G.Y.; Li, J.; Harding, J.J.; Varghese, A.M.; O'Reilly, E.M.; Yu, K.H. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer 2018, 18, 693.
58. Wang-Gillam, A.; Li, C.-P.; Bodoky, G.; Dean, A.; Shan, Y.-S.; Jameson, G.; Macarulla, T.; Lee, K.-H.; Cunningham, D.; Blanc, J.F.; et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomized, open-label, phase 3 trial. Lancet 2016, 387, 545–557.
59. Barkat, M.A.; Rizwanullah, M.; Beg, S.; Pottoo, F.H.; Siddiqui, S.; Ahmad, F.J. Paclitaxel-loaded Nanolipidic Carriers with Improved Oral Bioavailability and Anticancer Activity against Human Liver Carcinoma. AAPS PharmSciTech 2019, 20, 87.
60. Nasr, M.; Ghorab, M.K.; Abdelazem, A. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting. Acta Pharm. Sin. B 2015, 5, 79–88.
61. Grillone, A.; Riva, E.R.; Mondini, A.; Forte, C.; Calucci, L.; Innocenti, C.; de Julian Fernandez, C.; Cappello, V.; Gemmi, M.; Moscato, S.; et al. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid

Nanoparticles. Adv. Healthc. Mater. 2015, 4, 1681–1690

62. Lin, C.-C.; Lin, H.-Y.; Chi, M.-H.; Shen, C.-M.; Chen, H.-W.; Yang, W.-J.; Lee, M.-H. Preparation of curcumin microemulsions with food-grade soybean oil/lecithin and their cytotoxicity on the HepG2 cell line. Food Chem. 2014, 154, 282–290.
63. Qu, D.; Liu, M.; Huang, M.; Wang, L.; Chen, Y.; Liu, C.; Liu, Y. Octanoyl galactose ester-modified microemulsion system self-assembled by coix seed components to enhance tumor targeting and hepatoma therapy. Int. J. Nanomed. 2017, 12, 2045–2059.
64. Hu, H.; Xiao, C.; Wu, H.; Li, Y.; Zhou, Q.; Tang, Y.; Yu, C.; Yang, X.; Li, Z. Nanocolloidosomes with Selective Drug Release for Active Tumor-Targeted Imaging-Guided Photothermal/Chemo Combination Therapy. Appl. Mater. Interfaces 2017, 9, 42225–42238.
65. Zhang, X.; Lin, C.-C.; Chan, W.-K.-N.; Liu, K.-L.; Yang, Z.-J.; Zhang, H.-Q. Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation. Molecules 2017, 22, 1052.
66. Chang, M.; Wu, M.; Li, H. Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice. Drug Deliv. 2018, 25, 1984–1995.
67. Beg, M.S.; Brenner, A.J.; Sachdev, J.; Borad, M.; Kang, Y.-K.; Stoudemire, J.; Smith, S.; Bader, A.G.; Kim, S.; Hong, D.S. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investig. New Drugs 2017, 35, 180–188.
68. Yildirimer, L.; Thanh, N.T.; Loizidou, M.; Seifalian, A.M. Toxicology and clinical potential of nanoparticles. Nano Today 2011, 6, 585–607.
69. Azarnezhad, A.; Samadian, H.; Jaymand, M.; Sobhani, M.; Ahmadi, A. Toxicological profile of lipid-based nanostructures: Are they considered as completely safe nanocarriers? Crit. Rev. Toxicol. 2020, 50, 148–176.